减重手术与GLP-1受体激动剂治疗肥胖的比较
该队列研究比较了代谢减重手术(MBS)与GLP-1受体激动剂(GLP-1 RAs)在II/III级肥胖患者中的体重减轻和持续费用。
要点
- MBS与更大幅度的体重减轻相关(28.3% vs 10.3%)。
- GLP-1 RAs组持续药费是费用差异的主要驱动因素。
核心结论
- 在II/III级肥胖患者中,MBS与比GLP-1 RAs更大幅度的体重减轻和更低的持续费用相关。
- 需要进一步研究以确定MBS是否仍应被视为肥胖治疗的最后手段。
研究设计与样本
- 基于美国Highmark健康保险索赔数据库和Allegheny健康网络电子病历的队列研究。
主要发现
- 费用差异主要驱动因素为GLP-1 RAs组在整个随访第2年持续较高的药费。
- 体重数据子集分析显示,MBS组总减重百分比为28.3%,GLP-1 RAs组为10.3%(P<.001)。
临床怎么用
- 对于II/III级肥胖患者,MBS在体重减轻和2年费用方面可能优于GLP-1 RAs。
- 临床决策需结合患者偏好、长期依从性和费用考量综合评估。
局限性
- 体重减轻数据仅来自部分子集患者(MBS组1291例,GLP-1 RAs组257例)。
- 研究为观察性设计,可能存在未测量混杂因素。
- 随访时间有限,长期结局需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Obesity is a chronic condition with negative consequences for patients, the health care system, and society. The most effective treatment of class II and III obesity is metabolic bariatric surgery (MBS), which is usually considered a last resort. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have recently shown promising results. OBJECTIVE: To compare weight loss and ongoing costs associated with MBS and GLP-1 RAs in the US. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from the Highmark Health insurance claims database and the Allegheny Health Network electronic medical record in the US. Participants were patients with class II or III obesity treated with either MBS or GLP-1 RAs who were enrolled in Highmark insurance for at least 6 months prior to index treatment and had follow-up data available for at least 12 months. Using propensity score weighting, the populations were adjusted for differences in baseline spending, health care utilization, age, sex, comorbidities, and smoking status. Data were analyzed from July 2024 to July 2025. EXPOSURES: MBS (sleeve gastrectomy or gastric bypass) vs GLP-1 RAs (dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide, or tirzepatide). MAIN OUTCOMES AND MEASURES: The main outcomes were total weight loss and monthly ongoing costs (pharmacy, medical, and surgery costs) at baseline and over 2 years after index treatment. Mean adjusted costs were calculated using a linear mixed-effects model. RESULTS: Analyses included 30 458 patients (mean [SD] age, 50 [11] years; 20 118 [66.1%] female), with 14 101 undergoing MBS (mean [SD] follow-up, 34 [16] months) and 16 357 receiving GLP-1 RAs (mean [SD] follow-up, 32 [17] months). After propensity score weighting, baseline characteristics were comparable. The mean (SE) total costs over 2 years were $63 483 ($1563) for GLP-1 RAs and $51 794 ($1724) for MBS (P < .001). The main driver of this difference was higher sustained pharmacy costs in the GLP-1 RA group throughout year 2 of follow-up. Comparing weight loss data of 257 patients using GLP-1 RAs and 1291 patients who underwent MBS, total weight loss was greater for the MBS group (mean [SE], 28.3% [0.3%]) than the GLP-1 RA group (mean [SE], 10.3% [0.5%]) (P < .001). CONCLUSIONS AND RELEVANCE: These findings suggest that MBS was associated with more weight loss at lower ongoing costs compared with GLP-1 RAs in class II and III obesity. Further study is needed to determine if MBS should still be considered the last resort in treating obesity.
引用
- Barrett TS, Hafermann JO, Richards S, et al. Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. JAMA Surg. 2025. PMID: 40960852. doi:10.1001/jamasurg.2025.3590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。